2nd Quarter - Report

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$290,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 9, 2012 $290,000 Replaced
2nd Quarter - Amendment May 27, 2015 $290,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implications of ACA and Supreme Court decision; depression Rx access in Medicare, Medicaid, DOD, VA; lack of obesity Rx access in Part D;

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Manufacturing MAN

S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER New —
ANDREA WILKINSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: S. 3187 (112th)

Health Issues HCR

health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5 (112th)

Trade (domestic/foreign) TRD

Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act; Drug Import Safety issues; foreign drug supply chain issues; counterfiet drugs, serialization and development of tracibility model

LobbyistCovered position, as disclosed
DEBORAH LYNN WALTER —
ANDREA WILKINSON —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 319 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.